CN106456998B - 西格列汀丹宁酸盐复合物 - Google Patents

西格列汀丹宁酸盐复合物 Download PDF

Info

Publication number
CN106456998B
CN106456998B CN201580020211.4A CN201580020211A CN106456998B CN 106456998 B CN106456998 B CN 106456998B CN 201580020211 A CN201580020211 A CN 201580020211A CN 106456998 B CN106456998 B CN 106456998B
Authority
CN
China
Prior art keywords
sitagliptin
tannin
complex
oral dosage
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580020211.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456998A (zh
Inventor
W.奥姆万查
R.伯拉奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CN106456998A publication Critical patent/CN106456998A/zh
Application granted granted Critical
Publication of CN106456998B publication Critical patent/CN106456998B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580020211.4A 2014-04-17 2015-04-13 西格列汀丹宁酸盐复合物 Active CN106456998B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461980641P 2014-04-17 2014-04-17
US61/980641 2014-04-17
PCT/US2015/025504 WO2015160678A1 (en) 2014-04-17 2015-04-13 Sitagliptin tannate complex

Publications (2)

Publication Number Publication Date
CN106456998A CN106456998A (zh) 2017-02-22
CN106456998B true CN106456998B (zh) 2020-07-28

Family

ID=54324454

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580020211.4A Active CN106456998B (zh) 2014-04-17 2015-04-13 西格列汀丹宁酸盐复合物

Country Status (12)

Country Link
US (1) US9833463B2 (enExample)
EP (1) EP3131631B1 (enExample)
JP (1) JP6523328B2 (enExample)
KR (1) KR102351813B1 (enExample)
CN (1) CN106456998B (enExample)
AU (1) AU2015247921B2 (enExample)
BR (1) BR112016023839A8 (enExample)
CA (1) CA2945681A1 (enExample)
ES (1) ES2932383T3 (enExample)
MX (1) MX374598B (enExample)
RU (1) RU2696588C2 (enExample)
WO (1) WO2015160678A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201818969A (zh) * 2016-10-19 2018-06-01 日商帝化製藥股份有限公司 在生體內之藥物溶出控制用組成物
US11096890B2 (en) 2017-09-29 2021-08-24 Merck Sharp & Dohme Corp. Chewable dosage forms containing sitagliptin and metformin
WO2025090920A1 (en) * 2023-10-25 2025-05-01 Piton Therapeutics, Inc. Compositions and methods for treating dysfunction of glucose metabolism and/or regulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035198A2 (en) * 2005-07-25 2007-03-29 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2007050485A2 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
CN101600346A (zh) * 2006-12-14 2009-12-09 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
CN102388047A (zh) * 2009-02-11 2012-03-21 力奇制药公司 西他列汀的新盐

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5663415A (en) 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
WO2000069810A1 (en) 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
RU2269354C2 (ru) 1999-09-28 2006-02-10 Байер Корпорейшн Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
BR0210357A (pt) 2001-06-11 2004-06-29 Shire Biochem Inc Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20030083354A1 (en) 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US20030114535A1 (en) 2001-12-14 2003-06-19 Jame Fine Chemicals, Inc. Dextrochlorpheniramine tannate
US6670370B1 (en) 2001-12-14 2003-12-30 Jame Fine Chemicals, Inc. Dextromethorphan tannate
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
JP2007504230A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
EP1667524A4 (en) 2003-09-23 2009-01-14 Merck & Co Inc NEW CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYLPEPTIDASE IV INHIBITOR
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
US20050202050A1 (en) 2004-03-12 2005-09-15 Kiel Jeffrey S. Single tank process for preparing tannate liquid and semi-solid dosage forms
WO2006033848A1 (en) 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
US8003672B2 (en) * 2008-04-21 2011-08-23 Merck Sharp & Dohme Corp. CB-1 receptor modulator formulations
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035198A2 (en) * 2005-07-25 2007-03-29 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2007050485A2 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
CN101600346A (zh) * 2006-12-14 2009-12-09 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
CN102388047A (zh) * 2009-02-11 2012-03-21 力奇制药公司 西他列汀的新盐

Also Published As

Publication number Publication date
EP3131631A1 (en) 2017-02-22
EP3131631A4 (en) 2017-11-29
KR20160145008A (ko) 2016-12-19
RU2696588C2 (ru) 2019-08-05
US9833463B2 (en) 2017-12-05
US20170042922A1 (en) 2017-02-16
BR112016023839A8 (pt) 2023-04-11
ES2932383T3 (es) 2023-01-18
JP6523328B2 (ja) 2019-05-29
AU2015247921A1 (en) 2016-10-13
MX2016013588A (es) 2017-01-26
RU2016144695A (ru) 2018-05-21
WO2015160678A1 (en) 2015-10-22
MX374598B (es) 2025-03-06
AU2015247921B2 (en) 2019-07-11
KR102351813B1 (ko) 2022-01-18
BR112016023839A2 (pt) 2017-08-15
RU2016144695A3 (enExample) 2018-10-11
EP3131631B1 (en) 2022-11-16
CA2945681A1 (en) 2015-10-22
JP2017511350A (ja) 2017-04-20
CN106456998A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
EP1594499B1 (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
US20040131676A1 (en) Dosage forms containing a PPI, NSAID, and buffer
TW201302198A (zh) 含有納布啡（ｎａｌｂｕｐｈｉｎｅ）之藥學組成物及其用途
US20090075950A1 (en) Dosage Forms Containing A PPI, NSAID And A Buffer
KR101156054B1 (ko) 안정한 에페리손 함유 서방성 의약조성물
TWI606848B (zh) 包含格米列汀與美氟明的組合藥物及其製備方法
CA2870130A1 (en) Compositions and methods for treating cough
CN106456998B (zh) 西格列汀丹宁酸盐复合物
US20190314353A1 (en) Pharmaceutical Compositions Comprising Alpelisib
CN107582536B (zh) 一种枸橼酸铋钾口腔粘贴片及其制备方法
CN1414847A (zh) 含吡喹酮的缓释抗蠕虫组合物
WO2023247949A1 (en) An orodispersible pharmaceutical composition of baclofen and its process of preparation
WO2005105109A1 (en) Oral modified-release lozenges and their preparation method
CN1758904A (zh) 非甾体抗炎药物的给药方案
US20040009221A1 (en) Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
TW202146005A (zh) 結腸釋放用穩定塗佈的丁酸鹽
EP1608341A1 (en) Water-soluble tablets of metformin
US9265757B2 (en) Methods of administering antihistamines
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
TW202440149A (zh) 口服glp促效劑之藥物組合物
WO2025171802A1 (zh) 雷贝拉唑药物组合物、其制备方法及应用
EA034152B1 (ru) Антимикробные композиции с шипучими веществами
WO2019030610A1 (en) PHARMACEUTICAL COMPOSITIONS WITH DUAL DIRECTLY COMPRESSIBLE MEDICAMENT RELEASE
CN108159032A (zh) 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220907

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Patentee before: MERCK SHARP & DOHME Corp.